Advertisement

Osteoporosis International

, Volume 29, Issue 5, pp 1049–1055 | Cite as

Estrogen therapy for osteoporosis in the modern era

  • V. A. Levin
  • X. Jiang
  • R. Kagan
Concise Clinical Review

Abstract

Menopause predisposes women to osteoporosis due to declining estrogen levels. This results in a decrease in bone mineral density (BMD) and an increase in fractures. Osteoporotic fractures lead to substantial morbidity and mortality, and are considered one of the largest public health priorities by the World Health Organization (WHO). It is therefore essential for menopausal women to receive appropriate guidance for the prevention and management of osteoporosis. The Women’s Health Initiative (WHI) randomized controlled trial first proved hormonal therapy (HT) reduces the incidence of all osteoporosis-related fractures in postmenopausal women. However, the study concluded that the adverse effects outweighed the potential benefits on bone, leading to a significant decrease in HT use for menopausal symptoms. Additionally, HT was not used as first-line therapy for osteoporosis and fractures. Subsequent studies have challenged these initial conclusions and have shown significant efficacy of HT in various doses, durations, regimens, and routes of administration. These studies support that HT improves BMD and reduces fracture risk in women with and without osteoporosis. Furthermore, the studies suggest that low-dose and transdermal HT are less likely associated with the adverse effects of breast cancer, endometrial hyperplasia, coronary artery disease (CAD), and venous thromboembolism (VTE) previously observed in standard-dose oral HT regimens. Given the need for estrogen in menopausal women and evidence supporting the cost effectiveness, safety, and efficacy of HT, we propose that HT should be considered for the primary prevention and treatment of osteoporosis in appropriate candidates. HT should be individualized and the once “lowest dose for shortest period of time” concept should no longer be used. This review will focus on the prior and current studies for various HT formulations used for the prevention and treatment of osteoporosis, exploring the safety profile of low-dose and transdermal HT that have been shown to be safer than oral standard-dose HT.

Keywords

Bone mineral density (BMD) Hormone therapy (HT) Menopause Osteoporosis 

Notes

Compliance with ethical standards

Conflict of interest

None for VL and XJ, R Kagan has received research grants and support from Therapeutics MD (paid to Sutter Health), and has served as a consultant to Amgen, Merck, and Pfizer.

References

  1. 1.
    American College of Obstetrics and Gynecologists (2016) Practice Bulletin Number 129: OsteoporosisGoogle Scholar
  2. 2.
    Kosla S, Cauly J, Compston J et al (2017) Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res 32(3):424–430CrossRefGoogle Scholar
  3. 3.
    Gambacciani M, Levancini M (2014) Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Prz Menopauzalny 13(4):213–220PubMedPubMedCentralGoogle Scholar
  4. 4.
    Jin J (2017) Hormone therapy for primary prevention of chronic conditions in postmenopausal women. JAMA 318(22):2265CrossRefPubMedGoogle Scholar
  5. 5.
    Cauley JA, Robbins J, Chen Z, Women’s Health Initiative Investigators et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738CrossRefPubMedGoogle Scholar
  6. 6.
    Anderson GL, Limacher M, Assaf AR, Women’s Health Initiative Steering Committee et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRefPubMedGoogle Scholar
  7. 7.
    Sheu A, Center J (2017) Osteoporosis in postmenopausal women: key aspects of prevention and treatment. Med Today 18(4):29–38Google Scholar
  8. 8.
    de Villliers TJ, Stevenson JC (2012) The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric 15:263–266CrossRefGoogle Scholar
  9. 9.
    Richman S, Edusa V, Fadiel A, Naftolin F (2006) Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy. Menopause 13(1):148–155CrossRefPubMedGoogle Scholar
  10. 10.
    Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMedGoogle Scholar
  11. 11.
    Fletcher SW, Colditz GA (2002) Failure of estrogen plus progestin therapy for prevention. JAMA 288(3):366–368CrossRefPubMedGoogle Scholar
  12. 12.
    Shulman LP (2008) Transdermal hormone therapy and bone health. Clin Interv Aging 3(1):51–54CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    The North American Menopause Society (2017) The 2017 hormone therapy position statement of the North American Menopause Society. Menopause: J N Am Menopause Soc 24(7):728–753CrossRefGoogle Scholar
  14. 14.
    Baber RJ, Panay N, Fenton A, the IMS Writing Group (2016) 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19(2):109–150CrossRefPubMedGoogle Scholar
  15. 15.
    Qaseem A, Forciea MA, McLean RM et al (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166(11):818–839CrossRefPubMedGoogle Scholar
  16. 16.
    National Collaborating Centre for Women’s and Children’s Health (UK). Menopause: full guideline. London: National Institute for Health and Care Excellence (UK); 2015 Nov 12. (NICE Guideline, No. 23.) 11, long-term benefits and risks of hormone replacement therapy (HRT) Available at https://www.ncbi.nlm.nih.gov/books/NBK343458/. Accessed 9 Jan 2018
  17. 17.
    Warming L, Ravn P, Christiansen C (2005) Levonorgestrel and 17 beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis. Maturitas 50:78–85CrossRefPubMedGoogle Scholar
  18. 18.
    Abdi F, Mobedi H, Bayat F, Mosaffa N, Dolatian M, Tehrani F (2017) The effects of transdermal estrogen delivery on bone mineral density in postmenopausal women: a meta-analysis. Iranian J of Pharm Res 16(1):380–389Google Scholar
  19. 19.
    Scarabin P-Y, Oger E, Plu-Bureau G et al (2003) Differential association of oral and transdermal estrogen-replacement therapy with venous thromboembolism risk. Lancet 362:428–432CrossRefPubMedGoogle Scholar
  20. 20.
    Canonico M, Oger E, Plu-Bureau G et al (2007) Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115:840–845CrossRefPubMedGoogle Scholar
  21. 21.
    Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P (2011) Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 18:1052–1059CrossRefPubMedGoogle Scholar
  22. 22.
    Olie V, Canonico M, Scarabin PY (2010) Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 17:457–463CrossRefPubMedGoogle Scholar
  23. 23.
    Renoux C, Dell’aniello S, Garbe E, Suissa S (2010) Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 340:c2519CrossRefPubMedGoogle Scholar
  24. 24.
    KEEPS report: KEEPS results give new insight into hormone therapy. Available at https://www.menopause.org/annual-meetings/2012-meeting/keeps-report. Accessed 9 Jan 2018
  25. 25.
    Cobin RH, Goodman NF (2017) American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause—2017 update. Endocr Pract 23(7):869–880CrossRefPubMedGoogle Scholar
  26. 26.
    Adami S, Rossini M, Zamberlan N, Bertoldo F, Dorizzi R, Lo Cascio V (1993) Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 17(3):191–196CrossRefPubMedGoogle Scholar
  27. 27.
    Stevenson JC, Crook D, Godsland IF, Lees B, Whitehead MI (1993) Oral versus transdermal hormone replacement therapy. Int J Fertil Menopausal Stud 38(Suppl 1):30–35PubMedGoogle Scholar
  28. 28.
    Crook D, Cust MP, Gangar KF et al (1992) Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 166(3):950–955CrossRefPubMedGoogle Scholar
  29. 29.
    Smith GI, Reeds DN, Okunade AL, Patterson BW, Mittendorfer B (2014) Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. J Clin Endocrinol Metab 99(7):E1306–E1310CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    West SG, Hinderliter AL, Wells EC, Girdler SS, Light KC (2001) Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women. Am J Obstet Gynecol 184:926–933CrossRefPubMedGoogle Scholar
  31. 31.
    Cacciatore B, Paakkari I, Hasselblatt R, Nieminen MS, Toivonen J, Tikkanen MI (2001) Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women. Am J Obstet Gynecol 184:904–909CrossRefPubMedGoogle Scholar
  32. 32.
    Boardman HM, Hartley L, Eisinga A et al (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 10(3):CD002229Google Scholar
  33. 33.
    Feeley K, Wells M (2001) Hormone replacement therapy and the endometrium. J Clin Pathol 54(6):435–440CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Ettinger B, Pressman A, Van Gessel A (2001) Low-dosage esterified estrogens opposed by progestin at 6-month intervals. Obstet Gynecol 98(2):205–211PubMedGoogle Scholar
  35. 35.
    Genant HK, Lucas J, Weiss S et al (1997) Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 157:2609–2615CrossRefPubMedGoogle Scholar
  36. 36.
    Lemaitre RN, Weiss NS, Smith NL et al (2006) Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med 166(4):399–404CrossRefPubMedGoogle Scholar
  37. 37.
    Smith NL, Heckbert SR, Lemaitre RN et al (2004) Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292(13):1581–1587CrossRefPubMedGoogle Scholar
  38. 38.
    Prestwood KM, Kenny AM, Unson C, Kulldorff M (2000) The effect of low dose micronized 17[beta]-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 85:4462–4469PubMedGoogle Scholar
  39. 39.
    Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M (2003) Ultralow-dose micronized 17[beta]-estradiol and bone density and bone metabolism in older women. A randomized controlled trial. JAMA 290:1042–1048CrossRefPubMedGoogle Scholar
  40. 40.
    Sharp CA, Evans SF, Risteli L, Risteli J, Worsfold M, Davie MWJ (1996) Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women. Eur J Clin Investig 26:763–771CrossRefGoogle Scholar
  41. 41.
    Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP (1996) Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 88:587–592CrossRefPubMedGoogle Scholar
  42. 42.
    Ettinger B, Ensrud KE, Wallace R et al (2004) Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 104(3):443–451CrossRefPubMedGoogle Scholar
  43. 43.
    Lindsay R, Gallagher C, Kleerekoper M et al (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287:2668–2676CrossRefPubMedGoogle Scholar
  44. 44.
    Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH (2001) Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 75(6):1065–1079CrossRefPubMedGoogle Scholar
  45. 45.
    Lobo RA, Bush T, Carr BR, Pickar JH (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76(1):13–24CrossRefPubMedGoogle Scholar
  46. 46.
    Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 75(6):1080–1087CrossRefPubMedGoogle Scholar
  47. 47.
    Pickar JH, Yeh I-T, Wheeler JE, Cunnane MF, Speroff L (2001) Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 76(1):25–31CrossRefPubMedGoogle Scholar
  48. 48.
    Lewiecki EM Prevention of osteoporosis, UpToDate. Available at https://www.uptodate.com/contents/prevention-of-osteoporosis?source=see_link#H3961780. Accessed 9 Jan 2018
  49. 49.
    Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359–2381CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Jiang X, Gruner M, Trémollieres F et al (2017) Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: a systematic review and meta-analysis. Bone 99:20–25CrossRefPubMedGoogle Scholar
  51. 51.
    Studd J (2009) Why are physicians reluctant to use estrogens for anything—or do they prefer ‘PROFOX’? Menopause Int 15:52–54CrossRefPubMedGoogle Scholar
  52. 52.
    Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7):637–645CrossRefPubMedGoogle Scholar
  53. 53.
    Studd J (2011) ‘PROFOX’—the post HRT nightmare. Climacteric 14:217–219CrossRefPubMedGoogle Scholar
  54. 54.
    Studd J (2009) Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. Climacteric 12:206–209CrossRefPubMedGoogle Scholar
  55. 55.
    Khastgir G, Studd JWW, Holland N et al (2001) Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab 86:289–295PubMedGoogle Scholar
  56. 56.
    Khastgir G, Studd J, Holland N et al (2001) Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporosis Int 12:465–470CrossRefGoogle Scholar
  57. 57.
    Muscat Baron Y, Brincat MP, Galea R, Calleja N (2007) Low intervertebral disc height in postmenopausal women with osteoporotic vertebral fractures compared to hormone-treated and untreated postmenopausal women and premenopausal women without fractures. Climacteric 10:314–319CrossRefPubMedGoogle Scholar
  58. 58.
    FA T’m, Pouilles JM, Ribot C (2001) Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 12:385–390CrossRefGoogle Scholar
  59. 59.
    Watts NB, Cauley JA, Jackson RD et al (2017) No increase in fractures after stopping hormone therapy: results from the women’s health initiative. J Clin Endocrinol Metab 102(1):302–308PubMedGoogle Scholar
  60. 60.
    An expert committee of the National Osteoporosis Foundation (2014) The clinician’s guide to prevention and treatment of osteoporosis. Available at https://www.rheumatology.org/Portals/0/Files/CLINICIAN%E2%80%99S%20GUIDE%20TO%20PREVENTION%20AND%20TREATMENT%20OF%20OSTEOPOROSIS.pdf. Accessed 9 Jan 2018
  61. 61.
    Lobo R, Pickar J, Stevenson J, Mack W, Hodis H (2016) Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis 254:282–290CrossRefPubMedGoogle Scholar
  62. 62.
    Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D (2005) Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 105(4):779–787CrossRefPubMedGoogle Scholar
  63. 63.
    Kaunitz AM (2014) Extended duration use of menopausal hormone therapy. Menopause 21(6):679–681CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  1. 1.Department of ObGynThe Reading Hospital of Tower HealthReadingUSA
  2. 2.Department of ObGynSidney Kimmel Medical College of Thomas Jefferson UniversityPhiladelphiaUSA
  3. 3.Department of Obstetrics, Gynecology and Reproductive SciencesUCSFSan FranciscoUSA
  4. 4.Sutter East Bay Medical FoundationBerkeleyUSA

Personalised recommendations